OBJECTIVE: To evaluate the relationship between serum insulin-like growth factor 1 (IGF-1), IGF-1 binding protein 1 (IGFBP-1), and IGF-1 binding protein 2 (IGFBP-2) and fasting insulin, fasting glucose, adiposity, and mortality in older adults. DESIGN: A prospective cohort study with mean follow-up of 6.2 years. SETTING: Participants were recruited and followed at two centers affiliated with academic medical institutions. PARTICIPANTS: Six hundred twenty-five men and women aged 70 and older and in good health at the time of enrollment. MEASUREMENTS: Serum IGF-1, IGFBP-1, and IGFBP-2; fasting serum insulin; fasting serum glucose; visceral fat; and total percent fat. RESULTS: Higher IGFBP-1 and higher IGFBP-2 were significantly associated with lower fasting insulin, lower fasting glucose, and lower adiposity, but higher IGFBP-1 and IGFBP-2 were associated with greater mortality. In multivariate adjusted models, the hazard ratio for all-cause mortality was 1.48 (95% confidence interval (CI)=1.14-1.92) per standard deviation (SD) increase in IGFBP-2 and 1.34 (95% CI=1.01-1.76) per SD increase in IGFBP-1. No association was found between IGF-1 and all-cause mortality. CONCLUSIONS: Higher IGFBP-1 and IGFBP-2 are associated with lower adiposity and decreased glucose tolerance but also with greater all-cause mortality. Higher levels of serum IGF-1 binding protein (IGFBP) may indicate greater IGF-1 activity and thus represent an association between higher IGF-1 activity and mortality in humans.
OBJECTIVE: To evaluate the relationship between serum insulin-like growth factor 1 (IGF-1), IGF-1 binding protein 1 (IGFBP-1), and IGF-1 binding protein 2 (IGFBP-2) and fasting insulin, fasting glucose, adiposity, and mortality in older adults. DESIGN: A prospective cohort study with mean follow-up of 6.2 years. SETTING:Participants were recruited and followed at two centers affiliated with academic medical institutions. PARTICIPANTS: Six hundred twenty-five men and women aged 70 and older and in good health at the time of enrollment. MEASUREMENTS: Serum IGF-1, IGFBP-1, and IGFBP-2; fasting serum insulin; fasting serum glucose; visceral fat; and total percent fat. RESULTS: Higher IGFBP-1 and higher IGFBP-2 were significantly associated with lower fasting insulin, lower fasting glucose, and lower adiposity, but higher IGFBP-1 and IGFBP-2 were associated with greater mortality. In multivariate adjusted models, the hazard ratio for all-cause mortality was 1.48 (95% confidence interval (CI)=1.14-1.92) per standard deviation (SD) increase in IGFBP-2 and 1.34 (95% CI=1.01-1.76) per SD increase in IGFBP-1. No association was found between IGF-1 and all-cause mortality. CONCLUSIONS: Higher IGFBP-1 and IGFBP-2 are associated with lower adiposity and decreased glucose tolerance but also with greater all-cause mortality. Higher levels of serum IGF-1 binding protein (IGFBP) may indicate greater IGF-1 activity and thus represent an association between higher IGF-1 activity and mortality in humans.
Authors: Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham Journal: Lancet Date: 2002-05-18 Impact factor: 79.321
Authors: Annewieke W van den Beld; Werner F Blum; Huibert A P Pols; Diederick E Grobbee; Steven W J Lamberts Journal: Eur J Endocrinol Date: 2003-06 Impact factor: 6.664
Authors: Shreyasee Amin; B Lawrence Riggs; Elizabeth J Atkinson; Ann L Oberg; L Joseph Melton; Sundeep Khosla Journal: J Bone Miner Res Date: 2004-03-22 Impact factor: 6.741
Authors: Gail A Laughlin; Elizabeth Barrett-Connor; Michael H Criqui; Donna Kritz-Silverstein Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: S Savastano; A Barbato; C Di Somma; B Guida; G Pizza; L Barrea; S Avallone; M Schiano di Cola; P Strazzullo; A Colao Journal: J Endocrinol Invest Date: 2012-07-09 Impact factor: 4.256
Authors: Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan Journal: Eur J Endocrinol Date: 2019-02-01 Impact factor: 6.664
Authors: Robert C Kaplan; Petra Bùzková; Anne R Cappola; Howard D Strickler; Aileen P McGinn; Laina D Mercer; Alice M Arnold; Michael N Pollak; Anne B Newman Journal: J Clin Endocrinol Metab Date: 2012-03-22 Impact factor: 5.958
Authors: Nathan K Lebrasseur; Sara J Achenbach; L Joseph Melton; Shreyasee Amin; Sundeep Khosla Journal: J Bone Miner Res Date: 2012-10 Impact factor: 6.741
Authors: William R Swindell; Steven R Cummings; Jason L Sanders; Paolo Caserotti; Caterina Rosano; Suzanne Satterfield; Elsa S Strotmeyer; Tamara B Harris; Eleanor M Simonsick; Peggy M Cawthon Journal: Rejuvenation Res Date: 2012-05-18 Impact factor: 4.663
Authors: Masanobu Kawai; Anne C Breggia; Victoria E DeMambro; Xinchun Shen; Ernesto Canalis; Mary L Bouxsein; Wesley G Beamer; David R Clemmons; Clifford J Rosen Journal: J Biol Chem Date: 2011-03-03 Impact factor: 5.157
Authors: Marcello Maggio; Chiara Cattabiani; Fulvio Lauretani; Stefania Bandinelli; Francesca De Vita; Elisabetta Dall'Aglio; Andrea Corsonello; Fabrizia Lattanzio; Giuseppe Paolisso; Luigi Ferrucci; Gian Paolo Ceda Journal: J Gerontol A Biol Sci Med Sci Date: 2013-05-13 Impact factor: 6.053
Authors: Robert C Kaplan; Garrett Strizich; Chino Aneke-Nash; Clara Dominguez-Islas; Petra Bužková; Howard Strickler; Thomas Rohan; Michael Pollak; Lewis Kuller; Jorge R Kizer; Anne Cappola; Christopher I Li; Bruce M Psaty; Anne Newman Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958
Authors: Gang Xi; Melissa A Solum; Christine Wai; Laura A Maile; Clifford J Rosen; David R Clemmons Journal: Endocrinology Date: 2013-08-27 Impact factor: 4.736